Hims & Hers Stock Drops After Amazon Says It Will Offer Hair-Loss Treatments
Shares of Hims & Hers slid after Amazon.com said it would offer cheap treatments for concerns like hair loss, skin care and erectile dysfunction, directly competing with the telehealth startup. Amazon on Thursday launched the treatments through its One Medical telehealth service,
Walt Disney’s earnings beat Wall Street estimates, Super Micro Computer extends losses, and Cisco posts fiscal first-quarter ...
Health and wellness platform Hims & Hers Health, Inc. (NYSE:HIMS), which has gained traction for its obesity-related ...
Hims & Hers (HIMS) is down -17.7%, or -$4.88 to $22.72. Published first on TheFly – the ultimate source for real-time, ...
Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...
Investors with a lot of money to spend have taken a bullish stance on Hims & Hers Health HIMS. And retail traders ...
In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide ...
Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback